BOSTON (AP) _ Keryx Biopharmaceuticals Inc. (KERX) on Thursday reported a loss of $21.9 million in its first quarter.
The Boston-based company said it had a loss of 18 cents per share.
The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 19 cents per share.
The biopharmaceutical company posted revenue of $21.8 million in the period.
Keryx Biopharma shares have climbed 11 percent since the beginning of the year. The stock has declined 26 percent in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on KERX at https://www.zacks.com/ap/KERX